Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3677701 | 0.81 | KCNQ2 (0.53) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3676553 | 0.75 | PTPN11 (0.47) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3672056 | 0.75 | ALDH1A1 (0.52) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3682386 | 0.72 | GRIN2D (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3676017 | 0.72 | KCNQ2 (0.64) | — | |
| SCHEMBL8572968 | 0.71 | GRIN2D (0.46) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL32671633 | 0.69 | PTPN11 (0.60) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3679813 | 0.69 | KCNQ2 (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8569458 | 0.69 | CETP (0.50) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13002326 | 0.67 | NOTUM (0.61) | ALDH1A1HPGDHTTSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367684-B2 | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367684-B2 | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367684-B2 | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2170861-B1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2170861-B1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2170861-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | Valeant Pharmaceuticals International (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20080318979-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318979-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318979-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157404-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157404-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318979-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | KCNH2, KCNA6, KCNA1 | ALDH1A1 799/4885GRIN2D 601/4885GRIN3B 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.